Acta Pharmacologica Sinica, Published online: 10 November 2026; doi:10.1038/s41401-026-01962-y Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis
Xing-yu Lin, Zhi-hui Lin, Yang-jing Xue, Mi-yun Hu, Yan-min Chen, Jia-liang Tian et al. Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis. // Acta Pharmacologica Sinica. – 2026. – DOI: 10.1038/s41401-026-01962-y. – URL: https://www.nature.com/articles/s41401-026-01962-y
Xing-yu Lin, Zhi-hui Lin, Yang-jing Xue, Mi-yun Hu, Yan-min Chen, Jia-liang Tian, Sen-xu Wang, Bao-kang Jiang, Yu-qi Lv, Lei Li, & Kang-ting Ji (2026). Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01962-y
Xing-yu Lin, et al. “Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis.” Acta Pharmacologica Sinica, 2026. doi:10.1038/s41401-026-01962-y.
@article{Lin2026,
title = {Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis},
author = {Lin, Xing-yu and Lin, Zhi-hui and Xue, Yang-jing and Hu, Mi-yun and Chen, Yan-min and Tian, Jia-liang and Wang, Sen-xu and Jiang, Bao-kang and Lv, Yu-qi and Li, Lei and Ji, Kang-ting},
journal = {Acta Pharmacologica Sinica},
year = {2026},
doi = {10.1038/s41401-026-01962-y},
url = {https://www.nature.com/articles/s41401-026-01962-y}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...